Home
 News
 Web resources

 Tumours list
   Contribution



Projects

RARE UROLOGIC TUMOURS
   General information
   Urologic tumour list
     Contribution

RARE MELANOMA
   General information
   Rare melanoma list
     Contribution

RARE SKIN TUMOURS
   General information
   Skin tumor list
     Contribution

RARE BREAST CANCER

(GLS - italian project)
   Info generali
   Scheda dati

HINT-OUT
   General information
   Design
   System
   Objectives
   Registration
   Member area

 

partially supported by



News

24/09/2003 - GISTs: The revolution continues

Gastrointestinal stromal tumors (GISTs) are differentiated from other types of gastrointestinal mesenchymal tumors by the expression of c-kit receptor tyrosine kinase (KIT). More than 80% of GISTs have somatic mutations of the KIT gene and are considered to be caused by the mutations, a finding that allows the KIT inhibitor Imatinib mesylate (formerly known as STI-571) to be used successfully as a molecular target drug for GISTs. A few GISTs, however, do not show the gain-of-function mutations of KIT and, hence, are imatinib unresponsive. Japanese researchers found two types of gain-of-function mutations of PDGFR in 5 of 8 GISTs without KIT mutations but not in 10 GISTs with KIT mutations. The gain-of-function mutations of PDGFR gene might therefore play an important role on development of GISTs without KIT mutations. Read the editorial by William M. Grady as appeared on Gastroenterology 125(3):967-978, September 2003.

News Archive

3/8/2001 WHY?
17/11/2001 W.H.O. Collaborating Centre for Cancer Control of Uncommon Tumours
10/12/2001 On November 30th, in the hall of the S. Pio X Private Hospital of Milan, Italy, the
18/12/2001 Post-meeting survey
3/12/2002 QUIZ
5/5/2002 Dear Colleagues,Notebook Veri Kurtarma
29/01/2003 New publication on rare cancers !
28/07/2003 Thyroid Cancer Treatment Receives Orphan Drug Status
02/08/2003 Breast cancer in men Kiralık Ofis Ankara
28/10/2003 Lessons learned from the management of a rare genetic cancer.
17/11/2003 Successful photodynamic therapy for nonresectable cholangiocarcinoma.
07/01/2004 Gene associated with higher risk of melanoma in men
08/03/2004 Susceptibility to Common Adult Cancers in Retinoblastoma Survivors
29/03/2004 FDA Approves First Drug for mesothelioma
25/08/2004 Gene therapy cures malignant melanoma in mice
20/10/2004 FDA grants orphan drug status to two new anticancer drugs.
15/11/2004 New experimental drug for myeloproliferative disorder
20/01/2005 New leukemia treatment granted FDA orphan drug status.
28/02/2005 U.S. F.D.A. grants new orphan drug designation for a targeted therapeutic for head and neck cancer.
02/05/2005 Possible targets for a multiple myeloma vaccine
17/10/2005 Orphan drug troxacitabine approved for AML in EU
03/11/2005 FDA designes interleukin 21 as an orphan drug
01/12/2005 Zactima has received FDA orphan drug designation
25/01/2006 CETT Program for Rare Genetic Diseases
23/02/2006 New research studies of multiple myeloma